Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

July 3, 2007 at 4:46 PM

Cell Therapeutics’ Italian job

Cell Therapeutics executives will do a whirlwind tour of Milan this Friday — not precisely to attend the widely acclaimed mise-en-scene of Leonard Bernstein’s opera “Candide” at La Scala, but to meet with their Italian constituency.

The executives will brief some 30 shareholders on the company’s activities, the company said Tuesday. Executives will also meet with media during their visit.

Despite being based in Seattle, Cell Therapeutics’ has a strong Lombard connection: The company’s research is based in the Milanese suburb of Bresso since it acquired local biotech Novuspharma in 2003.

Most of Cell Therapeutics’ stockholders are based in Italy — which makes the outreach important, as the company has had trouble in the past to meet quorum requirements for shareholder events.

Italian-speaking shareholders can check the company’s Web site in Dante’s language.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►